Value&OutcomesSpotlight Logo

Value & Outcomes Spotlight Issues

Value & Outcomes Spotlight | November-December 2017 Vol. 3, No. 6
HEALTH POLICY
METHODOLOGY
MEETINGS
STUDENT CORNER
FROM OUR JOURNALS
Value & Outcomes Spotlight | September-October 2017 Vol. 3, No. 5
METHODOLOGY
AWARDS
STUDENT CORNER
FROM OUR JOURNALS
Conferences
Value & Outcomes Spotlight | July-August 2017 Vol. 3, No. 4
HEALTH POLICY
  • Accelerating Cures: Debating Speed vs. Safety *

    This article explores both sides of the controversial debate between speed versus safety in bringing new medicines to market for patients with rare diseases.

    COMMENTARY

    Thoughts on the Real-World Evidence Navigator
    Kristijan Kahler, RPh, PhD

    In this commentary, Kahler et al. share a perspective from the Real World Evidence Center of Excellence at Novartis on how the RWE Navigator can be used to inform overall evidence generation to support data driven decision making.

    GetReal: Real-World Evidence Navigator: Beyond the Hype *
    Heather Stagenga, MSc

    This article provides an introduction to the freely available RWE Navigator, a tool designed to address an unmet need for guidance on the role of real-world evidence in health care decision making.

METHODOLOGY
Q & A AND MORE
BOARD OF DIRECTORS
STUDENT CORNER
AWARDS
FROM OUR PUBLICATIONS
20TH ANNUAL EUROPEAN CONGRESS
Value & Outcomes Spotlight | May-June 2017 Vol. 3, No. 3
Value and Outcomes Spotlight June 2017
Letter from the Editor
Outgoing Presidential Address
HEALTH POLICY
METHODOLOGY
BOSTON MEETING
HIGHLIGHTS
AWARDS
STUDENT CORNER
FROM OUR JOURNALS
LATIN AMERICA CONFERENCE
Value & Outcomes Spotlight | March-April 2017 Vol. 3, No. 2
HEALTH POLICY
METHODOLOGY
Q & A AND MORE
VALUE IN HEALTH INFORMATION
ISPOR NEWS
Student Corner
Value & Outcomes Spotlight | January-February 2017 Vol. 3, No. 1
METHODOLOGY
HEALTH POLICY
Q & A AND MORE
ISPOR NEWS
Student Corner
Meetings
Value & Outcomes Spotlight | November/December 2016 Vol. 2, No. 6
HEALTH POLICY
  • Behavioral Economics and Shifting Behavior of Patients Towards Better Health *
    Kevin Volpp

    Noting that 80% of large companies provide incentives to their employees to practice better health behaviors, Dr. Volpp discusses several case studies in which behavioral economists and corporate leaders have together tried to maximize employee participation in health behavior improvement programs through incentives.

    Irrationality in Health Care *
    Douglas E. Hough

    Dr. Hough discusses the work of Daniel Kahneman, a behavioral psychologist, and how Kahneman’s observations and concepts may be used in behavioral economics to help explain rationality and irrationality in peoples’ health care decision making.

    Performance-Based Managed Entry Agreements for Medicines: Much Needed, but Not Feasible? *
    François Lucas

    Although it is difficult to predict the future, performance-based managed entry agreements are bound to be used more often based on the need to manage access to innovative therapies with immature data at launch, emerging appetite of payers for real-world evidence, integration of databases and improving sophistication of pharma market access teams.

    Perception of Anti-TNF Biosimilars among Payer Stakeholders in the United Kingdom, France, Germany, Italy, and Spain *
    Siva Narayanan

    In this article, the authors report the perception of anti-TNF biosimilars among payer stakeholders in the big-5 European countries, their rating of level of comfort with extrapolation of clinical data, quality of clinical and economic data available for novel compound evaluations and the perception of suitable target population for biosimilars.

METHODOLOGY
  • A Primer on Latent Class Analysis *
    Earnest H. Law

    This article introduces latent class analysis, an increasingly popular method for clustering individuals, and provides an overview of its theory and applications in outcome research.

VALUE IN HEALTH and VALUE IN HEALTH REGIONAL ISSUES INFORMATION
ISPOR NEWS
Student Corner
ISPOR in Action
Meetings
ISPOR Awards
Value & Outcomes Spotlight | September/October 2016 Vol. 2, No. 5
METHODOLOGY
HEALTH POLICY
Q & A AND MORE
ISPOR NEWS
Student Corner
Meetings
ISPOR Awards
Value & Outcomes Spotlight | July/August 2016 Vol. 2, No. 4
HEALTH POLICY
METHODOLOGY
Q & A AND MORE
ISPOR NEWS
Student Corner
Meetings
ISPOR in Action
ISPOR Awards
Value & Outcomes Spotlight | May/June 2016 Vol. 2, No. 3
VOS May/June 2016
Letter from the Editor
President’s Message

HEALTH POLICY
METHODOLOGY
  • An Introduction to Unit-of-Analysis Error *
    Maya Hanna, Elisabeth Oehrlein, Eleanor Perfetto
    This article emphasizes the importance of determining whether unit of analysis errors are present when using study results to inform health care decision making.

Q & A AND MORE
ISPOR NEWS
Meetings
Student Corner
ISPOR Awards
ISPOR in Action
Value & Outcomes Spotlight | March/April 2016 Vol. 2, No. 2
METHODOLOGY
  • Horizon Scanning: Identifying and Estimating Future Impact of Emerging Innovations on US Health Care *
    In this article, ECRI Institute staff describes the AHRQ Healthcare Horizon Scanning System and recently commissioned cost analyses as presented at last year’s ISPORs 20th Annual International Meeting in Philadelphia, PA, USA.

    A Real-World Research Perspective for Biosimilars *
    This article by Jacklyn L.F. Bosco, is based on a presentation given during the “Distinguishing Biosimilarity: How Can We Generate Real-World Evidence to Support Decision-Making” issue panel at the ISPOR 20th Annual International Meeting in Philadelphia, PA, USA.

    Time-Dependent Confounders: Are They All the Same? *
    In this article, which is intended for students and early-career researchers, Mehmet Burcu et al. briefly describe the concepts of confounding, treatment assignment, and selection bias in observational research, and distinguish two distinct types of time-dependent confounding: 1) time-dependent confounding not affected by prior treatment, and 2) time-dependent confounding affected by prior treatment.

HEALTH POLICY
Q & A AND MORE
ISPOR NEWS
ISPOR in Action
Meetings
Student Corner
Value & Outcomes Spotlight | January/February 2016 Vol. 2, No. 1
VOS January-february 2016
Letter from the Editor
President’s Message

HEALTH POLICY
METHODOLOGY
Q & A AND MORE
ISPOR NEWS
Meetings
Student Corner
ISPOR in Action
Value & Outcomes Spotlight | November/December 2015 Vol. 1, No. 6
HEALTH POLICY
METHODOLOGY
ISPOR NEWS
Meetings
ISPOR Awards
Student Corner
ISPOR in Action
Value & Outcomes Spotlight | September/October 2015 Vol. 1, No. 5
METHODOLOGY
HEALTH POLICY
ISPOR NEWS
Meetings
ISPOR Awards
Student Corner
ISPOR in Action
Value & Outcomes Spotlight | July/August 2015 Vol. 1, No. 4
METHODOLOGY
HEALTH POLICY
ISPOR NEWS
Meetings
ISPOR Board of Directors
ISPOR Awards
Student Corner
ISPOR in Action
Value & Outcomes Spotlight | May/June 2015 Vol. 1, No. 3
METHODOLOGY
HEALTH POLICY
ISPOR NEWS
Meetings
ISPOR in Action
Student Corner
In Memoriam
Value & Outcomes Spotlight | March/April 2015 Vol. 1, No. 2
HEALTH POLICY
ISPOR NEWS
Value & Outcomes Spotlight | January/February 2015 Vol. 1, No. 1
HEALTH POLICY
Early Scientific Advice from Regulators and HTA
  • An EMA Perspective *
    Shelia Killalea explains the procedures and key benefits of engaging with the EMA for Scientific Advice, with a focus on the parallel HTA/EMA procedure.

    A NICE Perspective *
    In this article, Leeza Osipenko gives a brief overview of NICE Scientific Advice service.

    The EUnetHTA Perspective *
    In this article, Mira Pavlovic will present the EUnetHTA perspective on the early dialogues between manufacturers, health technology assessment (HTA) bodies and regulators on initial evidence generation for relative effectiveness and cost effectiveness assessment.

    The Industry Perspective *
    Jens Grueger comments on the industry perspective on scientific advice from regulators and HTA bodies by touching upon initial expectations and concerns, key insights, critical success factors, and the future outlook.
METHODOLOGY
  • Question is Not Whether but How to use MCDA *
    In this article, Rob Baltussen outlines the present use of various criteria in reimbursement decisions on health technologies, and evaluates the potential of MCDA to guide these decisions.

    Three Questions to Ask when Examining MCDA *
    In this article Karl Claxton identified three questions that need to be addressed when considering the use of MCDA: 1) which criteria or attributes should be included; 2) what weights should be assigned to performance against them, and 3) what attributes of benefit are displaced due to additional costs.
ISPOR NEWS
Meetings
Board of Directors
ISPOR in Action
Student Corner